Dolan: 50,000 to 90,000 people die annually from SUDEP seizures
Eric Dolan · 704: A Son Saving His Mom With Health Tech Product That Recognizes Seizures · Jun 28, 2017 · at 12:18
Eric Dolan, co-founder and CEO of Newton, discusses the severity of epilepsy and mortality from Sudden Unexpected Death in Epilepsy (SUDEP).
0:00 / 0:09exact quote · 9.5s
720p mp4 · rendered on demand · StarZero watermark
“A lot of people actually die per year because of seizures around 50 to 90,000. So from a condition called SUDEP, sudden unexplained death and epilepsy patients.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Eric Dolan
Dolan: Chronic disease lead gen is more predictable than SaaS
“Because these are chronic diseases, people have to fulfill these scripts every single month. So it is more predictable. It's actually a lot more predictable than let's say Even in a couple other SaaS businesses, you know, if someone moves from, you know, from …”
Newton monetizes via lead generation, cutting patient drug costs up to 90%
“And the way we make money is through lead generation, so we work with partners to actually reduce the cost of your drugs of up to 80 to 90%, and we get paid to do so.”
Dolan: Newton can lower Keppra's price from $150 to $9
“I've been able to get the cost of a drug from an individual for, let's say Keppra from Keppra is an anti-epileptic drug. Through our service, I can get it from 150 dollars to nine dollars.”
Dolan: Epilepsy patients often fake paper log data right before doctor visits
“Even people who do do the paper logs, he actually finds that they don't actually record it throughout. They, like, they remember just before the appointment. Fake all the data. Now he's making a medical decision based off known fake data.”
Newton targets a $1 million run rate in 2017
“We're looking to do about a million dollar run rate this year”
Newton plans transition from pharma lead gen to market intelligence
“Our initial model is looking at how we can be a lead gen model for pharmaceutical in the pharmaceutical industry, but long-term, because we are collecting a lot of data we would want to transition more to a market intelligence company.”